tbuckley/cabot-search huggingface dataset:
Medical Students
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Thyrotoxicosis After a Single Ingestion of Levothyroxine
Authors: Stanley E. Von Hofe
Journal: JAMA (1977)

THERE HAVE been relatively few studies on the metabolic effects of a single ingestion or injection of a large amount of levothyroxine sodium.<sup>1-3</sup>No information is available on the amount which might be required to cause clinical thyrotoxicosis or the time of appearance of symptoms after ingestion. This report details an unusual case of clinical thyrotoxicosis caused by a single ingestion of levothyroxine. Serial clinical observations and thyroid function studies were obtained, including thyroxine and triiodothyronine radioimmunoassays (T<sub>4</sub>[RIA] and T<sub>3</sub>[RIA], respectively) and thyrotropin (TSH) measurements. <h3>Report of a Case</h3> A 31-year-old woman was treated with iodine 131 for Graves disease in 1973. Hypothyroidism subsequently developed, and she was maintained on a regimen of 0.15 mg levothyroxine sodium daily. On Jan 25, 1976, she ingested approximately one hundred 0.1-mg tablets of levothyroxine. She vomited two hours after ingestion, but the content of the vomitus was not
Systemic Lupus Erythematosus—Survival Patterns
Authors: Daniel J. Wallace
Journal: JAMA (1981)

Six hundred nine private patients with systemic lupus erythematosus were followed up for a mean of ten years. Ninety percent were female; 79% were white. Three hundred sixty-nine received diagnosis before 1970, and 234 after. Three hundred seventy-nine did not have nephritis; 230 did. The overall ten-year survival was 79% (87% without nephritis, 65% with nephritis). Male patients did consistently worse than female patients. No overall white vs nonwhite difference was noted. The presence of nephrotic syndrome at the onset of nephritis was a poor prognostic sign, but its development later was not. Patients younger than 16 years without nephritis have an excellent prognosis. One hundred twenty-eight patients died (82 with nephritis, 46 without nephritis). The most common causes of death were renal disease and sepsis. Improved survival of this series may reflect closer follow-up, better nutritional status, and treatment at earlier stages of disease. (<i>JAMA</i>1981;245:934-938)
Preoperative measurement of segmental liver volume of donors for living related liver transplantation
Authors: S Kawasaki
Journal: Hepatology (1993)

Segmental liver volume determination by computed tomographic scan was carried out preoperatively in nine donors for living related liver transplantation. The calculated volume was compared with the graft size actually obtained by three types of donor hepatectomy. The volume of the left lateral segment (175 to 241 ml) and the left lobe (310 to 490 ml) varied markedly among the donors. The ratio of the left lobar to total liver volume also showed a wide range of values (23.2% to 35.9%). The value of the left lobar volume did not correlate positively with the donor's body weight, suggesting that graft size cannot be predicted only on the basis of the donor's body size. Segmental graft liver volume was estimated by use of computed tomographic scan, with acceptable accuracy on comparison with the graft volume actually obtained. In living related liver transplantation, the type of donor hepatectomy should be selected on the basis of the segmental liver volume of the donor in addition to the recipient's body size so that liver failure can be prevented in recipients and the donor's safety can be assured as far as possible. (HEPATOLOGY 1993;18:1115-1120).
Food Additives
Authors: Thomas H. Jukes
Journal: New England Journal of Medicine (1977)

Food additives are in trouble with the public. Fears have justifiably resulted from the banning of additives that had for years been tagged as "safe." Many people have become so suspicious of all food additives that some food manufacturers have removed them as an advertising device.The "health-food" stores have capitalized on the fear of "synthetic chemicals," and have helped to spread distrust. The very term "food additives" has become a "bad word." Dr. Lewis Thomas1 includes food additives in a list with strip-mining, offshore oil wells, kepone and supersonic transports. Mental rejection of food additives is encouraged by reading . . .
Influenza and Pneumococcal Vaccination Rates Among Persons With Diabetes Mellitus--United States, 1997
Journal: JAMA (2000)

Vaccination is an important public health intervention for reducing morbidity and mortality from influenza and pneumonia among persons with diabetes. A national health objective for 2000 is to increase influenza and pneumococcal vaccination rates to > or =60% among persons at high risk for complications from influenza and pneumonia, including persons with diabetes. Although the Advisory Committee on Immunization Practices (ACIP) recommends that all persons with diabetes be vaccinated, data from the 1993 Behavioral Risk Factor Surveillance System (BRFSS) showed that 40% of persons with diabetes reported receiving an influenza vaccination within the previous year, and 21% reported ever receiving a pneumococcal vaccination. To assess the vaccination rates among persons with diabetes in 52 reporting areas (i.e., 50 states, the District of Columbia, and Puerto Rico), CDC and the Council of State and Territorial Epidemiologists (CSTE) analyzed data from the 1997 BRFSS. This report summarizes the findings of this analysis, which indicate that most states did not reach the national health objectives for influenza and pneumococcal vaccination in their populations with diabetes.
Disabled
Authors: Mimi Emig
Journal: Annals of Internal Medicine (2015)

Ad Libitum7 July 2015DisabledMimi Emig, MDMimi Emig, MDFrom Grand Rapids, Michigan.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M14-2963 Audio Reading - “Disabled” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "Disabled," by M. Emig. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Set adriftToward unseen shores.The insincere,“You look great,”Echoes across the gulf.Searching eyes,Whispers of truth.“I heard she'sHad a rough year.”Don't tell meYou envyMy afternoon naps,PicturingBook and cat at your side,Perfectly placed rays of sunlight.I can't pull off dinnerWith a full night's sleep.Don't sayYou wish youCould drop weightWithout trying.I wage costly battlesOn mountains of food,Losing again.Clothes hangFrom my slight frame,Sails billowing in the wind.Spare meThis admirationOf my bravery,The way I faceIllness.I'd run the other wayIf only I could.These daysI can hardly walk roundThis small islandI inhabit.Your imagined world of ... Author, Article, and Disclosure InformationAffiliations: From Grand Rapids, Michigan.Current Author Address: Mimi Emig, MD; e-mail, [email protected]net. PreviousarticleNextarticle Advertisement Audio Reading - “Disabled” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "Disabled," by M. Emig. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics 7 July 2015Volume 163, Issue 1Page: 72KeywordsDisabilitiesFoodSleep ePublished: 7 July 2015 Issue Published: 7 July 2015 Copyright & PermissionsCopyright © 2015 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
ACTR-39. PHOTODYNAMIC THERAPY USING TALAPORFIN SODIUM AND SEMICONDUCTOR LASER COMBINED WITH MAXIMUM TUMOR RESECTION IMPROVES PROGNOSIS OF PATIENTS WITH GLIOBLASTOMA
Authors: Masayuki Nitta, Yoshihiro Muragaki, Takashi Maruyama, Soko Ikuta, Hiroshi Iseki, Shunsuke Tsuzuki, Takayuki Yasuda, Takakazu Kawamata
Journal: Neuro-Oncology (2016)

Photodynamic therapy (PDT) is a local therapy that utilizes biochemical reactions between photosensitizer, light and tissue oxygen. PDT using Talaporfin sodium has shown dramatic anti-tumor effects for various cancers including esophageal cancer. We have conducted a prospective phase II trial of PDT for malignant brain tumors between 2009 and 2012, and it was approved in 2013 in Japan. Since the approval, our institute has performed a prospective post-marketing surveillance study of PDT and we have treated 90 patients with malignant brain tumors. Here, we analyzed clinical results of this prospective study on PDT for glioblastoma patients. Sixteen patients (8 males and 8 females) with newly diagnosed glioblastoma were treated with PDT between March 2009 and August 2015. A maximum resection of the enhanced lesion using intraoperative MRI was followed by PD laser irradiation of the wall of the resection cavity for 6 locations on average. Fractionated radiotherapy (60 Gy) and concomitant temozolomide chemotherapy were given for all patients. The median PFS and OS and 2-year OS were 19.6 and 31.5 months and 63.9%, respectively. Compared to other 76 patients with glioblastoma who underwent surgical resection for the same period in our institute, their median PFS and OS were 6.9 and 21.0 months, respectively. There was statistically significant difference in PFS between two groups (P=0.018, HR= 0.49), however there was no statistical significance in OS (P=0.08, HR=0.51), probably because of the small size of the PDT group. There was no significant adverse effect apparently related to PDT in any of the patients. Among 12 patients who recurred, only 5 (41.7%) showed local recurrence and the rest (58.3%) showed distant recurrence or dissemination, suggesting good local control by PDT. As conclusion, PDT for glioblastoma appears to provide significant survival benefit for PFS. A randomized clinical trial is justified and is under planning.
Letter: Screening for sickle-cell disease.
Journal: BMJ (1974)

Case Age Gestation No. (yr) (weeks) Parity Prostaglandins, Dose and Route Comments References 1 N.S. 18 0 F2a 30 mg i.a.Cervical repair 1 2 16 21 0 F2ae 30 mg + 25 mg. 8hr later i.a.Cervical repair 2 3 19 20 0 F,a 30 mg + 25 mg at 8 hr + Twin pregnancy, 2 25 mg at 24 hr + 25 mg at last dose given 7 34 hr i.a.hr after artificial rupture of membranes 4 15 15 0 25 mg Foe i.a.+ ox.i.v.No cervical repair 3 5 17 15 0 50 mg F2a i.a.Cervical repair 3 6
The Cardplayers
Authors: GN Braman
Journal: Annals of Internal Medicine (2000)

Ad Libitum21 November 2000The CardplayersGeorge N. Braman, MDGeorge N. Braman, MDBronx, NY 10471 (Braman)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-133-10-200011210-00019 SectionsAboutFull Text ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail “Over the houses of the dead my shadow passes.”–“Le Cimitière marin,” Paul ValéryI see four cardplayers among the stonesIntent upon their game, they play their handIndifferent to departed souls or bones—The graves look on impassively and bland.I see this image from a passing train,Just one of many a successive scene—It hovers like a tune or old refrainand lingers like the daggers of a dream.Like a playful Caravaggio printOn a whitewashed canvas planned with skillThe cardplayers in melancholy tintPlay out their game, though oblivious stillTo the names etched on the indifferent stones,Their forfeit lives, their scattered whitewashed bones. Author, Article, and Disclosure InformationAffiliations: Bronx, NY 10471 (Braman)Corresponding Author: George N. Braman, 6142 Delafield Avenue, Bronx, NY 10471. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 21 November 2000Volume 133, Issue 10Page: 836KeywordsBoneGames ePublished: 21 November 2000 Issue Published: 21 November 2000 Copyright & PermissionsCopyright © 2000 by American College of Physicians. All Rights Reserved.Loading ...
Abuse at work drains people, money, and medical workplace not immune
Authors: T. Randall
Journal: JAMA (1992)

ABUSE in the workplace can plague a staff's morale, productivity, and health. In some recent studies, employees across all professions have reported that they experience abuse at work as much or more often than they do at home, and that this abuse contributes to a host of medical problems. For the medical profession, workplace abuse is a double-edged sword. Not only must it treat the many stress-related illnesses caused by abuse, and intervene to prevent their recurrence, but it must also cope with abuse that happens between its own professionals. The medical workplace, despite its dedication to health and well-being, is not immune from abusive staff members and the toll they exact on the people they work with. A recent survey of medical students, in which a high proportion reported suffering psychopathological consequences from abuse during their training (<i>JAMA</i>. 1991;267:692-694, 738), and the temporary resignation of Stanford neurosurgeon Frances K.
Reductive Dehalogenation of Bromoform in Aqueous Solution
Authors: Eric A. Betterton, Robert G. Arnold, Ronald J. Kuhler, Gregory A. Santo
Journal: Environmental Health Perspectives (1995)

The hybrid semiconducter-macrocycle catalyst TiO2-cobalt phthalocyanine promotes the solar photolysis of aqueous bromoform under anaerobic conditions.The major decomposition products are dibromoethane and HBr.Bromomethane and methane were produced only after prolonged photolysis (30 hr).Acetone, derived from added 2-propanol, was the only observed oxidation product.Preliminary experiments showed that electrolytic reduction of aqueous carbon tetrachloride at a vitamin B12-modified silver electrode produced the expected lower homologues but with surprisingly high yields of methane.
Abstract 1274: Partial reprogramming of melanoma cells confers drug resistance and increased vulnerability to channel antagonists
Authors: Karol Granados, Laura Hüser, Aniello Federico, Sachindra Sachindra, Gretchen Wolff, Viktor Umansky, Jochen Utikal
Journal: Cancer Research (2019)

Abstract During melanoma progression, tumor cells undergo phenotypic switching, increasing melanoma plasticity and resistance to mitogen-activated protein kinase inhibitors (MAPKi). We propose a partial reprogramming model to target melanoma therapy resistance. Here we show that partially reprogrammed cells are a less proliferative and more dedifferentiated cell population, expressing a gene signature for stemness and suppressing melanocyte-specific markers. To investigate the development of resistance to MAPKi, cells were exposed to BRAF and MEK inhibitors. Partially reprogrammed cells become less sensitive to MAPKi, showing increased cell viability and decreased apoptosis. Based on genome expression data, we evaluated potential targets to restore sensitivity to MAPKi in partially reprogrammed cells. One of our candidates showed promising results by increasing apoptosis and differentiation after sequential treatment with BRAF and MEK inhibitors, in partially reprogrammed cells and human BRAFi-resistant cells. In summary, we show that partial reprogramming of melanoma cells is a feasible in vitro model to study resistance to MAPKi. Moreover, we suggest our candidate as a target to restore sensitivity of resistant cells to MAPKi which has significant clinical implications in the development of resistance to current treatments against melanoma. Citation Format: Karol Granados, Laura Hüser, Aniello Federico, Sachindra Sachindra, Gretchen Wolff, Viktor Umansky, Jochen Utikal. Partial reprogramming of melanoma cells confers drug resistance and increased vulnerability to channel antagonists [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1274.
Medicine as an Art.
Journal: JAMA (2000)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cyclophosphamide May Be Effective in Severe Vasculitis
Journal: JAMA (1980)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Home uterine activity monitoring for preterm labor. Policy statement. US Preventive Services Task Force
Journal: JAMA (1993)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 9944: Temporal Relationship Between Major Hemorrhagic Events and Mortality among Patients with Recent Acute Coronary Syndrome: Insights from ATLAS ACS 2-TIMI 51
Authors: Yuri Pride, Satishkumar Mohanavelu, Jessica Mega, Eugene Braunwald, C. Michael Gibson
Journal: Circulation (2012)

Background: Multiple studies have demonstrated an association between hemorrhagic events and long-term mortality among patients with ACS. The goals of this analysis were to (1) describe risk factors associated with non-CABG-related TIMI major bleeding and (2) determine whether there was a temporal relationship in the association between hemorrhagic events and mortality. Methods and results: ATLAS ACS-TIMI 51 enrolled patients with recent ACS and followed them for clinical outcomes for a median of 13 months. Multivariable Cox regression analyses adjusting for treatment and baseline characteristics were used to determine independent risk factors for non-CABG-related TIMI major bleeding. To analyze the hazard ratio and time dependency of bleeding on mortality, we used iterative day-to-day landmark analyses after the hemorrhagic event. Of the 15,526 patients enrolled, 196 (1.26%) had a non-CABG-related TIMI major bleed. Independent predictors of non-CABG-related TIMI major bleeding (p&lt;0.10) included assignment to rivaroxaban, increasing age, male sex, diabetes mellitus, revascularization for the index event and region of enrollment. Non-CABG-related TIMI major bleeding was associated with a significantly increased risk of mortality, even after adjusting for baseline differences (HRadj 5.94, 95% CI 4.2-8.5, p&lt;0.001). However, in the iterative landmark analysis, the hazard ratio did not differ statistically from baseline risk by 12 days after the bleeding event (Figure). Furthermore, in a landmark analysis, there was no difference in mortality among 30-day survivors of major bleeding compared with propensity-matched controls (3.9% vs. 4.1%, p=NS). Conclusions: Among patients with recent ACS, major bleeding is associated with higher mortality, even after adjusting for differences in baseline characteristics. However, the relationship between major bleeding and mortality is no longer significant 12 days after the bleeding event.
Abstract 1918: A Fat1 Cadherin-Myocardin Regulatory Pathway Controls Smooth Muscle Cell Differentiation and Neointimal Formation in Response to Vascular Injury
Authors: Yueting Shang, Prameladevi Chinnasamy, Rong Hou, Nicholas E Sibinga
Journal: Circulation (2009)

Vascular smooth muscle cells (SMCs) play a central role in vascular remodeling in diseases such as atherosclerosis and restenosis. Vascular injury and mitogens induce robust expression of the atypi...